Uncategorized

It’s Men’s Health Month – Is prostate cancer prevention possible?

Urologist and prostate cancer specialist Dr. Michael Lazar talks about prevention and options for maintaining health after a cancer diagnosis. June is Men’s Health Month and the focus is on prostate cancer. Second only to skin cancer, prostate cancer is the most common cancer among men in the U.S. and the third most common cause of cancer related death today; lung cancer remains in the number one spot. Currently it is estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. Those at highest risk are men who have a family history of prostate cancer and black men, who are more than twice as likely to die from the disease as any other group. Although experts will say that there's [...]

2017-12-13T13:37:20+00:00 June 26th, 2017|

Doctors believe it’s important to discuss pros and cons of prostate cancer screening with patients

A new study finds that while a blood test that helps to screen for prostate cancer remains common, only 30 percent of men in a large national survey reported having a balanced discussion of the advantages and disadvantages of the screening with their doctor. Moreover, having such a discussion of both pros and cons has become less likely since the U.S. Preventive Services Task Force issued a recommendation against performing prostate-specific antigen (PSA) testing in 2012. "That only about a third of patients reported having a discussion of advantages and disadvantages is an alarming statistic," said study lead author Dr. George Turini III, clinical instructor in medical science at the Warren Alpert Medical School of Brown University and a urologist with the Southcoast Physician Group. [...]

2017-12-13T13:37:20+00:00 April 24th, 2017|

New research reveals evidence linking inflammation to increased prostate cancer risk

Dr. Michael Lazar of California HIFU discusses the latest research on prostate cancer which offers hope for future treatments and may help to prevent the disease from becoming aggressive. An interesting new study, conducted by Dr. Andrew Goldstein, an assistant professor of molecular biology and a team of UCLA researchers, highlights a previously unrecognized type of cell that is found in uncommonly high numbers in inflamed areas of the prostate gland. These cells are now thought to initiate prostate cancer in response to genetic mutations. The study results suggest inflammation increases overall risk for the disease by increasing the available number of affected cells that can develop into prostate cancer. “The findings from research such as this will hopefully lead to the development of better [...]

2017-12-13T13:37:21+00:00 January 3rd, 2017|

California HIFU is the Right Choice for Prostate Cancer Treatment

For the past five years, Chris Lockheed’s PSA numbers had been going up. Then, last November, a biopsy revealed that he had two tumors on his prostate. Chris, 68, started doing research into what kind of options for treatment were available to him. When a radiation specialist in Rohnert Park told him about Dr. Michael Lazar and the HIFU procedure, he did more homework. He found that Dr. Lazar had done hundreds of these procedures in Puerto Vallarta, and the treatment was given FDA approval last October. “Dr. Lazar explained everything, and he’s done over 300 of the procedures, that’s why I went to him. I felt very confident. I looked at all of the choices and said ‘this is for me’.” In March, Chris, [...]

2017-12-13T13:37:22+00:00 August 2nd, 2016|

Study Supports Hemiablation HIFU for Prostate Cancer

Story source: Renal & Urology News. Jody A. Charnow, Editor. February 10, 2016 High-intensity focused ultrasound (HIFU) hemiablation offers mid-term promising functional and oncologic outcomes in carefully selected patients with clinically localized prostate cancer (PCa), according to researchers. In a prospective cohort study of 50 patients who underwent HIFU ablation of a single lobe of the prostate, the 5-year actuarial metastases-free survival, cancer-specific survival, and overall survival rates were 93%, 100%, and 87%, respectively, Roland van Velthoven, MD, and colleagues at the Jules Bordet Institute in Brussels, Belgium, reported in Prostate Cancer and Prostatic Diseases (2016;19:79-83). The researchers documented complete continence (no pads) and erections sufficient for intercourse in 94% and 80% of patients, respectively. “Our study suggests that hemiablation HIFU is a valid mini-invasive focal therapy strategy, feasible [...]

2016-09-23T11:17:14+00:00 February 25th, 2016|

Recently FDA approved HIFU for Prostate Cancer makes news in Kentucky

HIFU is making news all over the United States now that it has achieved FDA approval. In the news video below HIFU Prostate Services physician partner, Dr. John Jurige speaks with Louisville's news station, WHAS about HIFU for prostate cancer. Dr. Jurige treated the first patients in the US with HIFU outside of a clinical trial on November 10, 2015. View the video below ... HIFU Prostate Services has partnered with Dr. Michael Lazar and San Francisco Surgery Center to establish a HIFU Center of Excellence in downtown San Franciso where patients can now receive the Sonablate HIFU treatment. Dr. Lazar also serves as Medical Director of HIFU Prostate Services, has been working with HIFU since 2007, and was one of three physicians who proctored [...]

2017-12-13T13:37:54+00:00 November 18th, 2015|

Validation of Focal Therapy for Prostate Cancer

From August 2015 Journal of Urology:  Study by New York University in which images from mpMRI identified prostate cancer before radical prostatectomy.  The pathologists then took the gland and did step-sections to pinpoint the actual tumor.  They found that a 9 mm "halo" of treatment around the imaged tumor boundaries would have covered 100% of the cancers.  Not 80%, not 90%, but 100%. The criticism of focal therapy has been the concern that the mpMRI images did not designate the entire tumor, thereby risking leaving some of the tumor untreated if only the imaged area was treated with HIFU.  Since HIFU treats in 3 mm shots, adding 3 shots around the imaged tumor boundaries should cover the entire lesion. Focal HIFU therapy spares non-cancerous prostate [...]

2017-12-13T13:37:55+00:00 September 17th, 2015|

New High Intensity Focused Ultrasound Minimally-Invasive Treatment for Prostate Cancer Pioneered by Dr. Michael Lazar Soon to Be Approved by FDA for Use in the U.S.

The use of a new technology called High Intensity Focused Ultrasound (HIFU) waves to treat prostate cancer without surgery on an out-patient basis moves closer to U.S. approval thanks to Dr. Michael J. Lazar, Jr. and other urologists utilizing this next-generation technology with patients in other nations. HIFU technology achieves pinpoint accuracy using an “acoustic scalpel” that destroys prostate cancer, while sparing healthy tissue and preserving nerves, urine flow and erectile function in a majority of cases compared with traditional procedures. U.S. Food and Drug Administration (FDA) approval of HIFU is expected following a study involving 100 men with prostate cancer recurrence after radiation. HIFU is eradicating cancer in 70 to 72 percent of these cases, compared with cryosurgery (freezing) that historically cures about 40 [...]

2017-12-13T13:37:55+00:00 May 8th, 2015|

International HIFU Physician Dr. Michael Lazar

It has been very exciting to be able to offer HIFU to men with prostate cancer the past 6 years. The utility of the procedure continues to grow, with the evolution from merely whole gland therapy to the possibility of focal therapy. With MRI imaging improvements, we can not only limit treatment to the cancer focus in appropriate men, we can now better determine which patients are likely to have successful outcomes with whole gland therapy. Tissue Change Monitoring (TCM) has inspired me to modify the treatment on whole glands to lessen the risk of complications. It is impressive that many of my patients have done the math and found HIFU to be a relative bargain due their ability to go right back to work. [...]

2015-07-06T16:41:55+00:00 May 7th, 2015|